Credit Industriel ET Commercial Buys 248,202 Shares of Alumis Inc. $ALMS

Key Points

• Credit Industriel ET Commercial increased its stake in Alumis Inc. by 178.8% by purchasing an additional 248,202 shares in the second quarter, bringing its total ownership to approximately 387,002 shares.
• Alumis has seen a mix of analyst ratings, with Wall Street Zen upgrading its rating to a "hold" and Morgan Stanley lowering their price target from $23.00 to $22.00 while maintaining an "overweight" rating.
• During its latest earnings report, Alumis reported ($1.17) EPS, missing the consensus estimate, but achieved revenue of $2.67 million, significantly exceeding expectations of $1.80 million.

Credit Industriel ET Commercial boosted its stake in shares of Alumis Inc. (NASDAQ:ALMS - Free Report) by 178.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 387,002 shares of the company's stock after buying an additional 248,202 shares during the quarter. Credit Industriel ET Commercial owned approximately 0.71% of Alumis worth $1,161,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blair William & Co. IL bought a new stake in shares of Alumis during the second quarter valued at approximately $200,000. BML Capital Management LLC bought a new stake in Alumis during the 1st quarter valued at $305,000. Invesco Ltd. bought a new stake in Alumis during the 1st quarter valued at $164,000. Jane Street Group LLC bought a new stake in Alumis during the 1st quarter valued at $111,000. Finally, Nuveen LLC bought a new stake in Alumis during the 1st quarter valued at $105,000.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Wall Street Zen upgraded Alumis from a "strong sell" rating to a "hold" rating in a report on Saturday, August 16th. Morgan Stanley decreased their price objective on Alumis from $23.00 to $22.00 and set an "overweight" rating for the company in a report on Friday, August 15th. Wells Fargo & Company initiated coverage on shares of Alumis in a report on Friday, July 25th. They issued an "overweight" rating and a $17.00 price target for the company. Weiss Ratings restated a "sell (e+)" rating on shares of Alumis in a report on Wednesday, October 8th. Finally, HC Wainwright restated a "buy" rating and issued a $14.00 price target on shares of Alumis in a report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Alumis presently has an average rating of "Moderate Buy" and an average price target of $20.17.

Alumis Trading Up 3.8%

NASDAQ ALMS opened at $4.61 on Tuesday. The company has a 50 day moving average price of $4.40 and a 200 day moving average price of $4.46. Alumis Inc. has a 52 week low of $2.76 and a 52 week high of $13.11.

Alumis (NASDAQ:ALMS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.06). The company had revenue of $2.67 million for the quarter, compared to analysts' expectations of $1.80 million. As a group, equities analysts forecast that Alumis Inc. will post -8.51 EPS for the current year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.